Novel therapeutic agents for B-cell lymphoma: developing rational combinations.
Craig B Reeder1, Stephen M Ansell
1Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA. reeder.craig@mayo.edu
Blood
|October 28, 2010
Summary
Novel targeted therapies show promise for non-Hodgkin lymphoma treatment. This review explores how new agents, targeting pathways or cell receptors, can integrate with current standard approaches.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Non-Hodgkin lymphoma treatment landscape is evolving with new targeted therapies.
- Emerging agents include small molecules and novel receptor-targeting drugs.
- These therapies impact signaling pathways, apoptosis, and the tumor microenvironment.
Purpose of the Study:
- To review the utility and potential role of novel targeted therapies in non-Hodgkin lymphoma.
- To focus on data supporting the integration of these agents into standard treatment protocols.
- To provide an overview of emerging therapeutic strategies for non-Hodgkin lymphoma.
Main Methods:
- Literature review of recent clinical trial data and preclinical studies.
- Analysis of single-agent activity and potential combination strategies.
- Focus on novel targeted agents including small molecules and receptor-based therapies.
Main Results:
- Several novel targeted therapies demonstrate activity in non-Hodgkin lymphoma.
- Most new agents show single-agent activity but are not sufficient for monotherapy.
- Data highlight potential integration of these agents into existing treatment paradigms.
Conclusions:
- Novel targeted therapies offer new avenues for non-Hodgkin lymphoma treatment.
- Combination strategies are likely necessary for optimal efficacy.
- Further research is needed to define the precise role of these agents in standard care.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...